4S-AF方案预测射频导管消融后房颤复发的临床应用

IF 1.9 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Reviews in cardiovascular medicine Pub Date : 2025-03-14 eCollection Date: 2025-03-01 DOI:10.31083/RCM26318
Naiyuan Cui, Haiwei Li, Weiping Sun, Zefeng Wang, Zhongyu Yuan, Botao Zhu, Yutong Liu, Huanfu Liu, Yongquan Wu, Xiaoping Zhang
{"title":"4S-AF方案预测射频导管消融后房颤复发的临床应用","authors":"Naiyuan Cui, Haiwei Li, Weiping Sun, Zefeng Wang, Zhongyu Yuan, Botao Zhu, Yutong Liu, Huanfu Liu, Yongquan Wu, Xiaoping Zhang","doi":"10.31083/RCM26318","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The 4S-AF scheme, which comprises four domains related to atrial fibrillation (AF), stroke risk (St), symptom severity (Sy), severity of AF burden (Sb), and substrate (Su), represents a novel approach for structurally characterizing AF. This study aimed to assess the clinical utility of the scheme in predicting AF recurrence following radiofrequency catheter ablation (RFCA).</p><p><strong>Methods: </strong>We prospectively enrolled 345 consecutive patients with AF who underwent initial RFCA between January 2019 and December 2019. The 4S-AF scheme score was calculated and used to characterize AF. The primary outcome assessed was AF recurrence after RFCA, defined as any documented atrial tachyarrhythmia episode lasting at least 30 seconds.</p><p><strong>Results: </strong>In total, 345 patients (age 61 (interquartile range (IQR): 53-68) years, 34.2% female, 70.7% paroxysmal AF) were analyzed. The median duration of AF history was 12 (IQR: 3-36) months, and the median number of comorbidities was 2 (IQR: 1-3), and 157 (45.5%) patients had left atrial enlargement. During a median follow-up period of 28 (IQR: 13-37) months, AF recurrence occurred in 34.4% of patients. After eliminating the Sy and St domains, both the 4S-AF scheme (hazard ratio (HR) 1.38, 95% confidence interval (CI): 1.19-1.59, <i>p</i> < 0.001) and severity of burden and substrate of atrial fibrillation (2S-AF) scheme scores (HR 1.59, 95% CI: 1.33-1.89, <i>p</i> < 0.001) were independent predictors of AF recurrence following RFCA. For each domain, we found that the independent predictors were Sb (HR 1.84, 95% CI: 1.25-2.72, <i>p</i> = 0.002) and Su (HR 1.71, 95% CI: 1.36-2.14, <i>p</i> < 0.001). Furthermore, the 4S-AF (area under the curve (AUC) 65.2%, 95% CI: 59.3-71.1) and 2S-AF scheme score (AUC 66.2%, 95% CI: 60.2-72.1) had a modest ability to predict AF recurrence after RFCA.</p><p><strong>Conclusions: </strong>The novel 4S-AF scheme is feasible for evaluating and characterizing AF patients who undergo RFCA. A higher 4S-AF scheme score is independently associated with AF recurrence after RFCA. However, the ability of the 4S-AF scheme to discriminate between patients at high risk of recurrence was limited.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"26 3","pages":"26318"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951279/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical Utility of the 4S-AF Scheme in Predicting Atrial Fibrillation Recurrence after Radiofrequency Catheter Ablation.\",\"authors\":\"Naiyuan Cui, Haiwei Li, Weiping Sun, Zefeng Wang, Zhongyu Yuan, Botao Zhu, Yutong Liu, Huanfu Liu, Yongquan Wu, Xiaoping Zhang\",\"doi\":\"10.31083/RCM26318\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The 4S-AF scheme, which comprises four domains related to atrial fibrillation (AF), stroke risk (St), symptom severity (Sy), severity of AF burden (Sb), and substrate (Su), represents a novel approach for structurally characterizing AF. This study aimed to assess the clinical utility of the scheme in predicting AF recurrence following radiofrequency catheter ablation (RFCA).</p><p><strong>Methods: </strong>We prospectively enrolled 345 consecutive patients with AF who underwent initial RFCA between January 2019 and December 2019. The 4S-AF scheme score was calculated and used to characterize AF. The primary outcome assessed was AF recurrence after RFCA, defined as any documented atrial tachyarrhythmia episode lasting at least 30 seconds.</p><p><strong>Results: </strong>In total, 345 patients (age 61 (interquartile range (IQR): 53-68) years, 34.2% female, 70.7% paroxysmal AF) were analyzed. The median duration of AF history was 12 (IQR: 3-36) months, and the median number of comorbidities was 2 (IQR: 1-3), and 157 (45.5%) patients had left atrial enlargement. During a median follow-up period of 28 (IQR: 13-37) months, AF recurrence occurred in 34.4% of patients. After eliminating the Sy and St domains, both the 4S-AF scheme (hazard ratio (HR) 1.38, 95% confidence interval (CI): 1.19-1.59, <i>p</i> < 0.001) and severity of burden and substrate of atrial fibrillation (2S-AF) scheme scores (HR 1.59, 95% CI: 1.33-1.89, <i>p</i> < 0.001) were independent predictors of AF recurrence following RFCA. For each domain, we found that the independent predictors were Sb (HR 1.84, 95% CI: 1.25-2.72, <i>p</i> = 0.002) and Su (HR 1.71, 95% CI: 1.36-2.14, <i>p</i> < 0.001). Furthermore, the 4S-AF (area under the curve (AUC) 65.2%, 95% CI: 59.3-71.1) and 2S-AF scheme score (AUC 66.2%, 95% CI: 60.2-72.1) had a modest ability to predict AF recurrence after RFCA.</p><p><strong>Conclusions: </strong>The novel 4S-AF scheme is feasible for evaluating and characterizing AF patients who undergo RFCA. A higher 4S-AF scheme score is independently associated with AF recurrence after RFCA. However, the ability of the 4S-AF scheme to discriminate between patients at high risk of recurrence was limited.</p>\",\"PeriodicalId\":20989,\"journal\":{\"name\":\"Reviews in cardiovascular medicine\",\"volume\":\"26 3\",\"pages\":\"26318\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951279/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reviews in cardiovascular medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.31083/RCM26318\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in cardiovascular medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/RCM26318","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:4S-AF方案包括心房颤动(AF)、卒中风险(St)、症状严重程度(Sy)、房颤负担严重程度(Sb)和基底(Su)四个相关域,代表了一种新的房颤结构表征方法。本研究旨在评估该方案在预测射频导管消融(RFCA)后房颤复发方面的临床应用。方法:我们前瞻性地招募了345名连续的房颤患者,他们在2019年1月至2019年12月期间接受了初始RFCA。计算4S-AF方案评分并用于表征房颤。评估的主要结果是RFCA后房颤复发,定义为任何记录的房性心动过速发作持续至少30秒。结果:共分析345例患者(年龄61岁(四分位间距:53-68),女性34.2%,阵发性房颤70.7%)。房颤病程中位数为12个月(IQR: 3-36),合并症中位数为2例(IQR: 1-3),左房扩大157例(45.5%)。中位随访28个月(IQR: 13-37), 34.4%的患者发生房颤复发。排除Sy和St结构域后,4S-AF方案(风险比(HR) 1.38, 95%可信区间(CI): 1.19-1.59, p < 0.001)和2S-AF方案评分(HR 1.59, 95% CI: 1.33-1.89, p < 0.001)是RFCA后房颤复发的独立预测因子。对于每个域,我们发现独立预测因子为Sb (HR 1.84, 95% CI: 1.25-2.72, p = 0.002)和Su (HR 1.71, 95% CI: 1.36-2.14, p < 0.001)。此外,5s -AF(曲线下面积(AUC) 65.2%, 95% CI: 59.3-71.1)和2S-AF方案评分(AUC 66.2%, 95% CI: 60.2-72.1)对RFCA后AF复发有一定的预测能力。结论:新的4S-AF方案可用于评估和表征接受RFCA的房颤患者。更高的4S-AF方案评分与RFCA后AF复发独立相关。然而,4S-AF方案区分高风险复发患者的能力有限。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical Utility of the 4S-AF Scheme in Predicting Atrial Fibrillation Recurrence after Radiofrequency Catheter Ablation.

Background: The 4S-AF scheme, which comprises four domains related to atrial fibrillation (AF), stroke risk (St), symptom severity (Sy), severity of AF burden (Sb), and substrate (Su), represents a novel approach for structurally characterizing AF. This study aimed to assess the clinical utility of the scheme in predicting AF recurrence following radiofrequency catheter ablation (RFCA).

Methods: We prospectively enrolled 345 consecutive patients with AF who underwent initial RFCA between January 2019 and December 2019. The 4S-AF scheme score was calculated and used to characterize AF. The primary outcome assessed was AF recurrence after RFCA, defined as any documented atrial tachyarrhythmia episode lasting at least 30 seconds.

Results: In total, 345 patients (age 61 (interquartile range (IQR): 53-68) years, 34.2% female, 70.7% paroxysmal AF) were analyzed. The median duration of AF history was 12 (IQR: 3-36) months, and the median number of comorbidities was 2 (IQR: 1-3), and 157 (45.5%) patients had left atrial enlargement. During a median follow-up period of 28 (IQR: 13-37) months, AF recurrence occurred in 34.4% of patients. After eliminating the Sy and St domains, both the 4S-AF scheme (hazard ratio (HR) 1.38, 95% confidence interval (CI): 1.19-1.59, p < 0.001) and severity of burden and substrate of atrial fibrillation (2S-AF) scheme scores (HR 1.59, 95% CI: 1.33-1.89, p < 0.001) were independent predictors of AF recurrence following RFCA. For each domain, we found that the independent predictors were Sb (HR 1.84, 95% CI: 1.25-2.72, p = 0.002) and Su (HR 1.71, 95% CI: 1.36-2.14, p < 0.001). Furthermore, the 4S-AF (area under the curve (AUC) 65.2%, 95% CI: 59.3-71.1) and 2S-AF scheme score (AUC 66.2%, 95% CI: 60.2-72.1) had a modest ability to predict AF recurrence after RFCA.

Conclusions: The novel 4S-AF scheme is feasible for evaluating and characterizing AF patients who undergo RFCA. A higher 4S-AF scheme score is independently associated with AF recurrence after RFCA. However, the ability of the 4S-AF scheme to discriminate between patients at high risk of recurrence was limited.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Reviews in cardiovascular medicine
Reviews in cardiovascular medicine 医学-心血管系统
CiteScore
2.70
自引率
3.70%
发文量
377
审稿时长
1 months
期刊介绍: RCM is an international, peer-reviewed, open access journal. RCM publishes research articles, review papers and short communications on cardiovascular medicine as well as research on cardiovascular disease. We aim to provide a forum for publishing papers which explore the pathogenesis and promote the progression of cardiac and vascular diseases. We also seek to establish an interdisciplinary platform, focusing on translational issues, to facilitate the advancement of research, clinical treatment and diagnostic procedures. Heart surgery, cardiovascular imaging, risk factors and various clinical cardiac & vascular research will be considered.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信